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Abstract
In 2012, the Australian Group on Antimicrobial 
Resistance (AGAR) conducted a community-onset 
period-prevalence survey of clinical Staphylococcus 
aureus isolated from hospital outpatients and 
general practice patients including nursing homes, 
long term care facilities and hospice patients. 
Day surgery and dialysis patients were excluded. 
Twenty-nine medical microbiology laboratories 
from all state and mainland territories partici-
pated. Isolates were tested by Vitek2® (AST-P612 
card). Results were compared with previous AGAR 
community surveys. Nationally, the proportion of 
S. aureus that were methicillin-resistant S. aureus 
(MRSA) increased significantly from 11.5% in 2000 
to 17.9% in 2012 (P<0.0001). Resistance to the 
non-ß-lactam antimicrobials varied between 
regions. No resistance was detected to vancomy-
cin, teicoplanin or linezolid. Resistance in methicil-
lin susceptible S. aureus was rare apart from eryth-
romycin (12.8%) and was absent for vancomycin, 
teicoplanin, linezolid and daptomycin. The propor-
tion of S. aureus characterised as health care-
associated MRSA (HA-MRSA) was 5.1%. Three 
HA-MRSA clones were characterised, with 72.9% 
and 26.4% of HA-MRSA classified as ST22-IV [2B] 
(EMRSA-15) and ST239-III [3A] (Aus-2/3 EMRSA) 
respectively. Multi-clonal community-associated 
MRSA (CA-MRSA) accounted for 12.5% of all 
S. aureus. Regional variation in resistance in MRSA 
was primarily due to the differential distribution 
of the 2 major HA-MRSA clones; ST239-III [3A] 
(Aus-2/3 EMRSA), which is resistant to multiple 
non-ß-lactam antimicrobials, and ST22-IV [2B] 
(EMRSA-15), which is resistant to ciprofloxacin and 
typically erythromycin. Although the majority of 
CA-MRSA were non-multi-resistant, a significant 
expansion of Panton-Valentine leukocidin (PVL) 
positive CA-MRSA clones has occurred nationally. 
The mean age of patients (31.7 years, 95% CI 
28.9–34.5) with a PVL positive CA-MRSA infection 
was significantly lower (P<0.0001), than the mean 
age of patients with a PVL negative CA-MRSA 
infection (55.7 years, 95% CI 50.7–60.6). This shift 
in the molecular epidemiology of MRSA clones in 
the Australian community will potentially increase 
the number of young Australians with skin and soft 
tissue infections requiring hospitalisation. Commun 
Dis Intell 2014;38(1):E59–E69.
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Introduction
Staphylococcus aureus continues to be the causative 
organism of a wide range of community-acquired 
infections ranging from relatively minor skin and 
soft tissue infections to serious and life threatening 
systemic sepsis with a high mortality.1,2 In Australia, 
methicillin-resistant S. aureus (MRSA) was first 
detected in Sydney in the 1960s,3 but really became 
an endemic problem in hospitals, in particular in 
the eastern states, with the appearance of a multi-
resistant strain, (Aus-2/3 EMRSA), in the 1970s and 
80s.4,5 In Australia, community-associated MRSA 
(CA-MRSA) strains emerged in the 1990s, initially 
in Western Australia and the Northern Territory,6–8 
and subsequently in the eastern states.9–11 These 
MRSA strains are generally less resistant to a range 
of antimicrobials and associated with skin and soft 
tissue infection (SSTI). Strains harbouring the genes 
encoding Panton-Valentine leukocidin (PVL) were 
first detected in Australia in the late 1990s (the South 
Western Pacific [SWP] or Oceania clone: ST30-IV 
[2B].12 The PVL positive Queensland clone (ST93-IV 
[2B]) was characterised in 2000 and is now the 
dominant CA-MRSA in Australia.13,14 Importation 
of several overseas PVL positive clones has occurred: 
USA300 (ST8-IV [2B]), the Bengal Bay Clone 
(ST772-V [5C2]), Taiwan CA-MRSA (ST59-V [5C2 
and 5]) and European CA-MRSA (ST80-IV [2B]).15 
PVL is associated with recurrent furunculosis and 
more severe infections including osteomyelitis, septi-
caemia and necrotising pneumonia.
The Australian Group on Antimicrobial Resistance 
(AGAR) has conducted surveillance of antimicro-
bial resistance in S. aureus for over 20 years.16 This 
surveillance role is very important given the ability 
of S. aureus strains to acquire new resistance and 
virulence determinants and to undergo rapid clonal 
expansion. Since the 1960s multiple waves of MRSA 
clones have occurred in Australia influencing the 
susceptibility profiles of the isolates seen in clinical 
practice. Results of previous AGAR surveys provide 
the only longitudinal record of the epidemiology of 
MRSA at a national level.17–19 Given the emergence 
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of hyper-virulent community MRSA strains, AGAR 
changed its methodology in 2000 to conduct surveys 
of community isolates biennially. The community-
based surveys performed in 2000, 2002, 2004 and 
2006 have been reported previously.20–22
The results of the 7th community-based survey of 
S. aureus infection conducted in 2012 are reported 
here.
Methods
Twenty-nine laboratories from all 8 Australian 
states and territories participated in the 2012 
S. aureus AGAR survey.
From 1 July to 30 November 2012 each laboratory 
collected up to 100 clinically significant consecutive 
S. aureus isolates from different patients. Isolates 
were collected from hospital outpatients. Day sur-
gery and dialysis patients were excluded. Isolates 
from nursing homes, long-term care facilities and 
hospice patients were included. Each S. aureus iso-
late was from an individual patient and was judged 
to have come from a potentially infected site.
Susceptibility methodology
All isolates were tested using the Vitek2® AST-
P612 card. All isolates with a penicillin minimum 
inhibitory concentration (MIC) of ≤0.125 mg/L 
were screened for the presence of ß-lactamase 
using nitrocefin or disc diffusion using a Penicillin 
10 unit disc (CLSI) or Penicillin 1 unit disc 
(EUCAST). High-level mupirocin resistance 
was determined by disc diffusion (200 ug). CLSI 
breakpoints were utilised for all antimicrobials23 
except fusidic acid (http://www.eucast.org/clini-
cal_breakpoints/). Isolates with an MIC in the 
intermediate resistance category have been called 
resistant in this report.
Epidemiological typing of methicillin-resistant 
Staphylococcus aureus
Of the 510 MRSA identified, 499 (97.8%) were 
referred to the Australian Collaborating Centre 
for Enterococcus and Staphylococcus Species 
(ACCESS) Typing and Research for epidemiologi-
cal typing.
Electrophoresis of chromosomal DNA using 
a contour-clamped homogeneous electric field 
DRIII System (Bio-Rad Laboratories Pty Ltd) was 
performed as previously described on all MRSA 
isolates.24 Multilocus sequence typing (MLST) 
and SCCmec typing was performed as previously 
described on selected MRSA isolates.25–27
PCR for the detection of PVL determinants was per-
formed as previously described on all MRSA isolates.28
Methicillin-resistant Staphylococcus aureus 
nomenclature
MRSA clones were defined by the combination 
of the multilocus sequence type (ST) and the 
SCCmec type.29 Clones are reported with their 
ST and SCCmec type followed by their col-
loquial name in parenthesis; e.g. ST22-IV [2B] 
(EMRSA-15). SCCmec nomenclature is used as 
proposed by the International Working Group 
on the Classification of Staphylococcal Cassette 
Chromosome Elements.30 Briefly, the structural 
type is indicated by a Roman numeral, with a 
lowercase letter indicating the subtype, and the 
ccr complex and the mec complex are indicated 
by an Arabic numeral and an uppercase letter 
respectively in parenthesis. Where there is an 
extra ccr element, this is indicated by ‘&’ and an 
Arabic numeral designating the ccr type. When 
there is an extra ccr element present whose pre-
cise location is unknown it is indicated by an ‘&’ 
and ccr number outside the parentheses. Clones 
were classified into two groups on the basis of 
previously published evidence: those implicated 
in healthcare-associated infection (HA-MRSA) 
and those implicated in CA-MRSA.
Clones that diverged at no more than one of the 
7 MLST loci were considered to belong to the 
same clonal complex (CC). Double locus variants 
were included in the same CC if the linking single 
locus variant was present in the MLST database 
(http://www.mlst.net/).
Statistical analysis
The difference between proportions was tested 
using a Chi-square test and Fisher’s exact test 
(GraphPad® Prism Software). Relative risk and 
95% confidence intervals (CI) were calculated 
using VassarStats (http://vassarstats.net).
Results
The survey included 2,844 isolates (Table 1) with 
the majority (1,792, 63.0%) being contributed by 
New South Wales, Queensland and Victoria.
SSTI specimens contributed the majority of 
isolates (2,575, 90.5%) followed by respiratory 
specimens (106, 3.7%) and bacteraemia (89, 3.1%). 
There were significantly (P<0.0001) more isolates 
causing non-invasive (2,740, 96.3%) than invasive 
(104, 3.7%) infections (Table 2).
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The proportion of S. aureus that were MRSA was 
17.9% (95% CI 16.6–19.4%) nationally (Table 3), 
ranging from 4.0% in the Australian Capital 
Territory to 25.5% in New South Wales.
The proportion of invasive isolates (blood/sterile 
body cavity sites) that were MRSA was 21.2% (95% 
CI 14.4–30.0%) and was similar (P=0.4037) to 
the proportion of non-invasive isolates at 17.8% 
(95% CI 16.4–19.3%) (Table 3). The proportion 
of MRSA was highest in blood at 21.3% (95% CI 
14.1–31.0%) (Table 4).
There were significant differences (P<0.0001) 
in the proportion of MRSA seen in different 
patient groups with patients from long term care 
facilities (46.7%, 95% CI 24.8–70.0%), patients 
attending emergency departments (20.9%, 95% CI 
18.9–23.1%) and hospital outpatients (17.0%, 95% 
CI 14.2–20.1%) having high rates of MRSA. In 
general practice patients the proportion of S. aureus 
that were MRSA was 12.7% (95% CI 10.5–15.3%).
Resistance in MRSA to non-ß-lactam antimicrobi-
als (with the exception of rifampicin, high-level 
mupirocin and fusidic acid) varied between regions 
(Table 5). Two isolates were non-susceptible to 
daptomycin. No resistance was detected to vanco-
mycin, teicoplanin or linezolid. There were differ-
ences in the proportion of isolates resistant to non-
ß-lactam antimicrobials in MRSA associated with 
Table 1: Staphylococcus aureus isolates, 
Australia, 2012, by state or territory
State or 
territory
Number of 
institutions Total %
ACT 1 100 3.5
NSW 7 693 24.4
NT 1 100 3.5
Qld 6 599 21.1
SA 3 296 10.4
Tas. 2 159 5.6
Vic. 5 500 17.6
WA 4 397 14.0
Total 29 2,844 100.0
Table 2: Source of Staphylococcus aureus 
isolates, Australia, 2012
Specimen source Number % 95% CI
Skin and soft tissue 2,575 90.5 89.4–91.6
Respiratory 106 3.7 3.1–4.5
Blood 89 3.1 2.6–3.8
Urine 58 2.0 1.6–2.6
Sterile body cavity 16 0.6 0.4–0.9
Total 2,844
 Invasive* 104 3.7 3.0–4.4
 Non-invasive 2,740 96.3 95.6–97.0
* Blood or sterile body cavity
Table 3: Proportion of Staphylococcus aureus that were methicillin resistant, Australia, 2012, by 
state or territory and source
State or 
territory
All isolates Invasive isolates* Non-invasive isolates
n/N % 95% CI n/N % 95% CI n/N % 95% CI
ACT 4/100 4.0 1.2–10.2 0/0 0.0 4/100 4.0 1.2–10.2
NSW 177/693 25.5 22.4–28.9 13/33 39.4 24.7–56.4 164/660 24.8 21.7–28.3
NT 24/100 24.0 16.6–33.3 1/2 50.0 9.5–90.6 23/98 23.5 16.1–32.8
Qld 103/599 17.2 14.4–20.4 2/17 11.8 2.0–35.6 101/582 17.4 14.5–20.7
SA 43/296 14.5 10.9–19.0 1/5 20.0 2.0–64.0 42/291 14.4 10.8–19.0
Tas. 9/159 5.7 2.9–10.6 0/11 0.0 0–30.0 9/148 6.1 3.1–11.3
Vic. 87/500 17.4 14.3–21.0 3/23 13.0 3.7–33.0 84/477 17.6 14.4–21.3
WA 63/397 15.9 12.6–19.8 2/13 15.4 3.1–43.5 61/384 15.9 12.6–19.0
Aus. 510/2,844 17.9 16.6–19.4 22/104 21.2 14.4–30.0 488/2,740 17.8 16.4–19.3
* Blood/sterile body cavity
Table 4: Proportion of Staphylococcus aureus 
that were methicillin resistant, Australia, 
2012, by specimen type
Source of infection n/N % 95% CI
Blood 19/89 21.3 14.1–31.0
Sterile body cavity 3/16 18.8 6.6–43.1
Skin and soft tissue 462/2,575 17.9 16.5–19.5 
Urine 10/58 17.2 9.6–28.9
Respiratory 16/106 15.1 9.5–23.1
Total 510/2,844 17.9 16.6–19.4
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various patient types. MRSA resistance for many 
antimicrobials was high in hospital outpatients, 
emergency and long-term care, which is consist-
ent with a higher proportion of these having been 
acquired in healthcare-related settings.
Susceptibility testing of methicillin sensitive 
S. aureus (MSSA) (Table 6) show resistance to 
non-ß-lactam antimicrobials remains uncommon 
except for erythromycin where overall resistance 
was 12.8% (95% CI 11.5–14.2%). All isolates were 
susceptible to vancomycin, teicoplanin, linezolid 
and daptomycin. Resistance to penicillin was high 
and in similar proportions ranging from 82.3% to 
90.8% across all regions.
Based on molecular typing, of the 499 MRSA 
referred to ACCESS Typing and Research, 28.9% 
(144) and 71.1% (355) were classified as HA-MRSA 
and CA-MRSA strains respectively. The mean age of 
patients with a CA-MRSA infection (40.6 years, 95% 
CI 37.8–43.4) was significantly lower (P<0.0001), 
than the mean age of patients with a HA-MRSA 
infection (69.8 years 95% CI 66.2–73.4) (Figure 1).
Throughout Australia, the percentage of S. aureus 
characterised as HA-MRSA was 5.1%, ranging 
from 1.0% in the Australian Capital Territory 
to 10.8% in New South Wales (Figure 1). Three 
HA-MRSA clones were identified: ST22-IV [2B] 
(EMRSA-15) (72.9% of HA-MRSA), ST239-III 
[3A] (Aus-2/3 EMRSA) (26.4%),and 1 isolate of 
ST5-II [2A] (New York Japan MRSA/USA100).
ST22-IV [2B] (EMRSA-15) has become the pre-
dominant HA-MRSA clone in the Australian com-
munity accounting for 21.0% of MRSA ranging from 
0% in the Northern Territory to 44.4% in Tasmania 
(Table 7). Typically PVL negative, 99% and 61% of 
ST22-IV [2B] (EMRSA-15) isolates were resistant 
to ciprofloxacin and erythromycin respectively.
ST239-III [3A] (Aus-2/3 EMRSA) accounted for 
7.6% of MRSA ranging from 0% in the Australian 
Capital Territory and Tasmania to 21.7% in the 
Northern Territory (Table 7). PVL negative 
ST239-III [3A] (Aus-2/3 EMRSA was typically 
resistant to tetracycline (100%), erythromycin 
(100%), gentamicin (97%),ciprofloxacin (92%), 
and cotrimoxazole (92%).
Throughout Australia, the percentage of S. aureus 
characterised as CA-MRSA was 12.5%, ranging 
from 3.0% in the Australian Capital Territory 
to 18.0% in the Northern Territory (Figure 2). 
Thirty-two CA-MRSA clones were identified by 
pulsed-field gel electrophoresis, corresponding 
to 25 MLST/SCCmec clones (Table 8). Overall, 
82.5% of CA-MRSA were classified into 6 clones: 
ST93-IV [2B] (Qld CA-MRSA) (36.3% of 
CA-MRSA);ST30-IV [2B] (SWP MRSA) (16.9%); 
ST1-IV [2B] (WA1) (13.5%); ST45-V [5C2&5] 
(WA84) (5.9%); ST78-IV [2B] (WA2) (5.1%); and 
ST5-IV [2B] (WA3) (4.8%).
Figure 1: Box plot of age of patients infected 
with community-associated methicillin-
resistant Staphylococcus aureus and 
healthcare-associated methicillin-resistant 
Staphylococcus aureus, Australia, 2012
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Figure 2: Percentage of Staphylococcus 
aureus characterised as healthcare-associated 
methicillin-resistant Staphylococcus aureus 
and community-associated methicillin-
resistant Staphylococcus aureus strains, 
Australia, 2012, by state or territory
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Table 8: Proportion of community-associated methicillin-resistant Staphylococcus aureus, 
Australia, 2012, by clone and Panton Valentine leukocidin carriage
Clone Clonal complex Alternative name n (%) PVL pos (%)
ST93-IV [2B] Singleton Queensland MRSA 129 (36.3) 127 (98.4)
ST30-IV [2B] 30 SWP MRSA 60 (16.9) 56 (93.3)
ST1-IV [2B] 1 WA1 48 (13.5) 3 (6.3)
ST45-V [5C2&5] 45 WA84 (Vic CA-MRSA) 21 (5.9) 0
ST78-IV [2B] 88 WA2 18 (5.1) 1 (5.6)
ST5-IV [2B] 5 WA3 17 (4.8) 5 (29.4)
ST73-IV [2B] 5 WA65 10 (2.8) 0
ST8-IV [2B] 8 USA300 10 (2.8) 9 (90.0)
ST952-V [5C2&5] 59 Taiwan A MRSA 5 (1.4) 5 (100)
ST59-V [5C2&5] 59 Taiwan MRSA 5 (1.4) 5 (100)
ST5-IV [2B] 5 WA121 4 (1.1) 4 (100)
ST6-IV [2B] 5 WA51 3 (0.8) 3 (100)
ST8-IV [2B] 8 WA5 3 (0.8) 0
ST953-IV [2B] 97 WA54 3 (0.8) 0
ST772-V [5C2] 1 Bengal Bay 2 (0.6) 2 (100)
ST1-V [5C2] 1 1 (0.3) 0
ST188-IV [2B] 1 WA38 1 (0.3) 0
ST5-IV [2B] 5 WA96 1 (0.3) 0
ST5-IV [2B] 5 WA71 1 (0.3) 1 (100)
ST5-V [5C2] 5 WA109 1 (0.3) 0
ST5-V [5C2] 5 1 (0.3) 0
ST835-IV [2B] 5 WA48 1 (0.3) 0
ST2471-V [5C2] 8 WA120 1 (0.3) 0
ST12-novel 12 WA59 1 (0.3) 0
ST30-V [5C2] 30 WA124 1 (0.3) 1 (100)
ST45-IV [2B] 45 WA75 1 (0.3) 0
ST59-IV [2B] 59 WA15 1 (0.3) 0
ST59-IV [2B] 59 WA55 1 (0.3) 1 (100)
ST72-IV [2B] 72 Korean Clone 1 (0.3) 0
ST577-IV [2B] 121 WA22 1 (0.3) 0
ST883-IV [2B] Singleton WA47 1 (0.3) 0
ST1303-IV [2B] U WA76 1 (0.3) 0
Total 355 223 (62.8)
PVL Panton Valentine leukocidin.
Percentage figures in parenthesis relate to CA-MRSA isolates.
Table 7: Proportion of methicillin-resistant Staphylococcus aureus characterised as ST22-IV [2B] 
(EMRSA-15) and ST239-III [3A] (Aus-2/3 EMRSA), Australia, 2012, by state or territory
ACT `NSW NT Qld SA Tas. Vic. WA Aus.
ST22-IV [2B] 25.0 34.3 0.0 9.9 11.9 44.4 21.2 12.7 21.0
ST239-III [3A] 0.0 8.7 21.7 3.0 4.8 0.0 14.1 1.6 7.6
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ST93-IV [2B] (Qld CA-MRSA) accounted for 
25.9% of MRSA ranging from 12.9% in Victoria 
to 47.8% in the Northern Territory (Table 9). PVL 
positive ST93-IV[2B] (Qld CA-MRSA) were typi-
cally resistant to the ß-lactam antimicrobials only 
(110/129) or additionally to erythromycin (17/129).
ST30-IV [2B] (SWP MRSA) accounted for 12.0% 
of MRSA ranging from 0% in the Australian 
Capital Territory to 25.7% in Queensland (Table 9). 
Overall 90% of PVL positive ST30-IV [2B] were 
resistant to the ß-lactam antimicrobials only.
ST1-IV [2B] (WA1) accounted for 9.6% of MRSA 
ranging from 0% in Tasmania and the Australian 
Capital Territory to 25.4% in Western Australia 
(Table 9). Typically PVL negative, 95.8% of isolates 
were non-multi-resistant (resistant to less than 
3 ß-lactam antimicrobials).
The remaining 3 major CA-MRSA clones, ST45-V 
[5C2&5] (WA84), ST78-IV [2B] (WA2) and 
ST5-IV [2B] (WA3) accounted for 4.2%, 3.6% and 
3.4% of MRSA respectively.
Overall, 94.4% of CA-MRSA were non-multi-
resistant, with 61.4% of isolates resistant to 
ß-lactam antimicrobials only. However, 20 isolates 
(5.6% of CA-MRSA) were multi-resistant includ-
ing 2 PVL positive ST772-V [5C2] (Bengal Bay 
MRSA) isolates, which, in addition to ß-lactam 
antimicrobials, were resistant to gentamicin, 
erythromycin, ciprofloxacin, and cotrimoxazole. 
Two CA-MRSA, ST188-IV [2B] (WA38) and 
ST8-IV [2B] (USA300), were resistant to 5 non-ß-
lactam antimicrobials: gentamicin, erythromycin, 
ciprofloxacin, cotrimoxazole and tetracycline; and 
gentamicin, erythromycin, ciprofloxacin, mupi-
rocin and tetracycline respectively.
PVL determinants were detected in 45.5% of 
MRSA:223 (62.8%) CA-MRSA (Table 8) and 
4 ST22-IV [2B] (EMRSA-15) isolates. In addition 
to ST93-IV [2B] (Qld CA-MRSA) and ST30-IV 
[2B] (SWP MRSA), PVL-positive CA-MRSA 
clones included the international clones ST8-IV 
[2B] (USA300), ST59-V [5C2&5] (Taiwan MRSA) 
and ST772-V [5C2] (Bengal Bay MRSA). The 
mean age of patients (31.7 years: 95% CI 28.9–34.5) 
with a PVL positive CA-MRSA infection was sig-
nificantly lower (P<0.0001) than the mean age of 
patients with a PVL negative CA-MRSA infection 
(55.7 years, 95% CI 50.7–60.6) (Figure 3).
Discussion
This survey demonstrates MRSA has become a 
significant burden in the Australian community. 
Over the 7 biennial AGAR community surveys 
(2000 to 2012), the percentage of S. aureus identified 
as MRSA has increased significantly (P<0.0001) 
by 6 percentage points over the 12-year period 
(11.5% in 2000 to 17.9% in 2012). Molecular typ-
Table 9: Proportion of methicillin-resistant Staphylococcus aureus characterised as community-
associated methicillin-resistant Staphylococcus aureus, Australia, 2012, by state or territory
ACT NSW NT Qld SA Tas. Vic. WA Aus.
ST93-IV [2B] (Qld) 25.0 21.5 47.8 37.6 33.3 22.2 12.9 23.8 25.9
ST30-IV [2B] (SWP) 0.0 8.7 13.0 25.7 9.5 22.2 7.1 6.3 12.0
ST1-IV [2B] (WA1) 0.0 6.4 4.3 8.9 14.3 0.0 5.9 25.4 9.6
ST45-V [5C2&5] (WA84) 0.0 2.9 0.0 2.0 2.4 0.0 15.3 0.0 4.2
ST78-IV [2B] (WA2) 25.0 0.6 0.0 1.0 7.1 11.1 2.4 14.3 3.6
ST5-IV [2B] (WA3) 25.0 1.7 0.0 5.0 2.4 0.0 4.6 4.8 3.4
Other 0.0 25.8 16.7 8.0 17.1 0.0 25.5 12.9 12.2
Figure 3: Box plot of age of patients infected 
with Panton Valentine leukocidin positive 
and Panton Valentine leukocidin negative 
community-associated methicillin-resistant 
Staphylococcus aureus, Australia, 2012
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Panton Valentine leukocidin positive community-associated 
methicillin-resistant Staphylococcus aureus: Mean age 
31.7 years (95% CI: 28.9–34.5)
Panton Valentine leukocidin negative community-associated 
methicillin-resistant Staphylococcus aureus: Mean age 
55.7 years (95% CI: 50.7–60.6)
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ing has shown this increase in community-onset 
MRSA has primarily been due to the emergence 
and expansion of non-multi-resistant clones.
In the 2012 study, resistance in MRSA to eryth-
romycin, ciprofloxacin, tetracycline, gentamicin, 
clindamycin and cotrimoxazole significantly 
varied across regions. These differences can be 
explained by the different MRSA clones in circula-
tion in each region; for example Aus-2/3 EMRSA 
(ST239-III), which is reliably resistant to gen-
tamicin, erythromycin, tetracycline, ciprofloxacin 
and cotrimoxazole are commonly found in New 
South Wales, the Northern Territory and Victoria.
There were significant differences in the propor-
tion of resistance to non-ß-lactam antimicrobials 
in MRSA associated with various patient types 
with gentamicin, tetracycline, ciprofloxacin, clin-
damycin, cotrimoxazole and fusidic acid resistance 
higher in hospital outpatients that other patient 
types. This is consistent with their having a higher 
proportion of healthcare-related acquisition.
In the 2012 study, apart from erythromycin, resist-
ance to the non-ß-lactam antimicrobials amongst 
the MSSA was uncommon. Over the 7 AGAR sur-
veys, no trends in resistance, increase or decrease, 
were evident for erythromycin, tetracycline, 
gentamicin or rifampicin. Nationally, small but 
significant increases were seen for clindamycin, 
ciprofloxacin, fusidic acid, high-level mupirocin 
and cotrimoxazole.
The mean age of patients with infections due to 
CA-MRSA strains (41 years; median 38 years) 
was found to be significantly lower (P<0.0001) 
than the mean age of patients with infections due 
to HA-MRSA strains (70 years; median 75 years). 
Although the percentage of S. aureus character-
ised as HA-MRSA in this survey (5.1%) was lower 
when compared with the 2010 survey (5.9%), 
ST22-IV [2B] (EMRSA-15) remains a major 
HA-MRSA clone in most Australian communities 
surveyed, accounting for 21.0% of all community-
onset MRSA infections. Of continuing concern 
has been the rapid emergence of this clone in the 
community in Victoria (0% in 2002 to 21.2% in 
2012), and New South Wales (18.0% in 2000 to 
34.3% in 2012). In 2012, CA-MRSA accounted for 
71.1% of MRSA and 12.5% of all S. aureus. Since 
2000, the percentage of S. aureus characterised as 
CA-MRSA has more than doubled (5.3% in 2000). 
As in previous surveys although CA-MRSA was 
multi-clonal (32 clones,) 82.5% of strains could 
be characterised into 6 clones. ST93-IV [2B] 
(Qld CA-MRSA), a PVL-positive clone, remains 
the most frequently isolated CA-MRSA clone in 
the Australian community accounting for 36.3% 
of all CA-MRSA and 25.9% of all MRSA infec-
tions. Overall, 62.8% of CA-MRSA were PVL 
positive, a 21% increase when compared with the 
2006 survey. The mean age of patients with PVL 
positive CA-MRSA infections (32 years; median 
29 years) was significantly lower (P<0.0001) 
than the mean age of patients with PVL nega-
tive CA-MRSA infections (56 years; median 
57 years). However, the increase in PVL-positive 
MRSA is not only due to the expansion of the 
ST93-IV [2B] clone but also due to ST30-IV [2B] 
(SWP MRSA) and due to the introduction of 
several international CA-MRSA clones including 
ST8-IV [2B] (USA300) ST59-V [5C2&5] (Taiwan 
CA-MRSA) and the hypervirulent multi-resistant 
ST772-V [5C2] (Bengal Bay). Four ST22-IV [2B] 
(EMRSA-15) isolates carrying the PVL determi-
nant were also identified. Acquisition of the PVL 
determinant in this clone, which has been dem-
onstrated to have enhanced transmission in the 
Australian community, continues to be a major 
public health concern.
In summary, resistance in MSSA remains 
uncommon with the exception of erythromycin 
and penicillin. Resistance in MRSA appears 
dynamic due to the success or decline of MRSA 
clones circulating in Australia. The national rate 
continues to rise in strains causing infections in 
people in the community. Since the initial AGAR 
community-onset S. aureus survey in 2000 there 
has been a significant increase in the percent-
age of patients with community onset MRSA 
infections in most regions of Australia, such that 
in 2012 one in 6 patients with a staphylococ-
cal infection have MRSA and one in eight are 
infected with a CA-MRSA clone. This makes the 
empiric choice for the correct antibiotic therapy 
of community S. aureus infections increasingly 
difficult. Of further concern is that this increase 
in MRSA has primarily been due to the expan-
sion of the PVL positive clones such as ST93-IV 
[2B] (Qld CA-MRSA) and ST30-IV [2B] (SWP 
CA-MRSA). This shift in the molecular epi-
demiology of MRSA clones in the Australian 
community will potentially increase the number 
of SSTIs in young Australians. As SSTIs caused 
by PVL-positive S. aureus frequently results in 
hospitalisation the emergence of these strains in 
the community as well as the detection of PVL-
positive HA-MRSA (EMRSA-15) is a major 
health concern.
A full detailed report on this study may be found 
on the AGAR web site: (http://www.antimicrobial-
resistance.com/) under AMR surveillance.
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